Sanofi's Aubagio meets primary in trial to prevent conversion to MS

Sanofi (Euronext:SAN; NYSE:SNY) said once-daily oral Aubagio teriflunomide met the primary endpoint vs. placebo in the Phase III TOPIC trial to prevent or delay conversion of clinically isolated syndrome (CIS) to clinically definite multiple sclerosis (MS). Specifically, Aubagio led to placebo-adjusted reductions in the risk of conversion to clinically definite MS over a two-year period of 37% in the 7 mg dose group (p=0.0271) and 43% in the 14 mg dose group (p=0.0087). The double-blind, international trial enrolled 618 patients who had experienced a first acute or sub-acute, well-defined neurological event consistent with demyelination, as well as onset of MS symptoms within 90 days of randomization and MRI scan showing at least two T2 lesions characteristic of MS. ...